ESTRO 2024 - Abstract Book

S997

Clinical - Gynaecology

ESTRO 2024

Material/Methods:

Twenty-two patients, regardless of programmed death ligand-1 (PD-L1) status, received toripalimab combined with concurrent chemoradiotherapy (CCRT). CCRT includes cisplatin (40 mg/m2, once a week for 5 weeks), radiotherapy (45-50.4Gy/25-28Fx, 5 fractions a week, followed by brachytherapy 24-30Gy/3-5Fx) and toripalimab was administered intravenously of 240mg on day 1, 22 and 43 during CCRT.

The primary endpoints were safety and 2-year progression-free survival (PFS). Secondary endpoints included 2 year local control (LC), local regional control, and overall survival (OS).

Results:

All patients completed CCRT and toripalimab treatment successfully. Grade Ⅲ and higher adverse events (AEs) were observed in 11 patients (11/22, 50%), and no patient had a grade Ⅴ AE. The objective response rate (ORR) was 100%. At data cutoff (June 30, 2023), the median follow-up was 31.8 months (9.5 to 37.8 months). The 2y PFS rate was 81.8%. The 2y LC and local regional control rate were both 95.5%, and the 2y OS rate was 90.9%.

Conclusion:

Toripalimab combined with CCRT achieved good tolerance and demonstrated promising anti-tumor effects in patients with locally advanced cervical cancer.

Keywords: cervical cancer, PD-1 inhibitor.

694

Digital Poster

A systematic review of incidence of vaginal toxicities following chemoradiation in cervical cancer

Shraddha Raj 1 , Rajiv Ranjan Prasad 2 , Swati Swati 1 , Rajesh kumar Singh 1 , Seema Devi 1 , Dinesh kumar sinha 1 , Richa Madhawi 1 , Kunal kishor 1 1 State Cancer Institute, Indira Gandhi Institute of Medical sciences, Radiation Oncology, Patna, India. 2 Jay Prabha Medanta Hospital, Radiation Oncology, Patna, India

Purpose/Objective:

Vagina is a unique organ which may be the target and an organ at risk (OAR) at the same time in radiation therapy of cervical cancer. Vaginal toxicity due to radiotherapy (RT) may lead to devastating quality of life (QoL) for the survivor. We conducted this systematic review to find the incidence of vaginal toxicities following concomitant chemoradiation.

Material/Methods: